Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Nov 11, 2025

Codexis Announces Signing of Lease for GMP Manufacturing Facility

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California.

GlobeNewsWire • Nov 10, 2025

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Codexis, Inc. ( CDXS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Georgia Erbez - CFO & Chief Business Officer Stephen Dilly Alison Moore - President, CEO & Director Britton Jimenez Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Chad Wiatrowski - TD Cowen, Research Division Presentation Operator Greetings, and welcome to the Codexis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded.

Seeking Alpha • Nov 7, 2025

Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.29 per share a year ago.

Zacks Investment Research • Nov 7, 2025

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

REDWOOD CITY, Calif. , Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics, today announced that they have entered into an evaluation agreement.

PRNewsWire • Oct 29, 2025

Codexis to Report Third Quarter 2025 Financial Results on November 6

REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

GlobeNewsWire • Oct 23, 2025

Codexis to Participate in Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, 2025, in New York, New York.

GlobeNewsWire • Aug 28, 2025

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Georgia L. Erbez - Chief Financial Officer Kevin Norrett - Chief Operating Officer Stephen George Dilly - President, CEO & Chairman Conference Call Participants Allison Marie Bratzel - Piper Sandler & Co., Research Division Brendan Mychal Smith - TD Cowen, Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Operator Welcome to Codexis Second Quarter 2025 Earnings Conference Call.

Seeking Alpha • Aug 13, 2025

Codexis Reports Second Quarter 2025 Financial Results

Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

GlobeNewsWire • Aug 13, 2025

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.32 per share a year ago.

Zacks Investment Research • Aug 13, 2025